# Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

> **NCT07657312** · PHASE2 · RECRUITING · sponsor: **Naresh Bumma** · enrollment: 35 (estimated)

## Conditions studied

- Cytokine Release Syndrome
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Infliximab
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Talquetamab
- **DRUG:** Teclistamab
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT07657312
- **Lead sponsor:** Naresh Bumma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657312, "Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*